Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals for the transition of a project into further drug discovery process.
Subscribe to our email newsletter
This milestone was reached in 2015 which will be recognised in the financial year 2015.
The agreement between Evotec and Janssen for this collaboration became effective on October 31, 2013. Johnson & Johnson Innovation facilitates the collaboration.
Under the terms of the agreement, Janssen and Evotec continue to collaborate to develop new drugs for Alzheimer’s disease. Janssen has the right to internalise selected targets and therapeutic candidates and progress them into pre-clinical and clinical development.
Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Evotec chief scientific officer Cord Dohrmann said: "Despite the significant challenges in identifying and prosecuting novel targets in the field of Alzheimer’s disease, our collaboration with Janssen continues to thrive as documented by this milestone.
"On the basis of an ever improving platform and an excellent team that is seamlessly integrated across both companies, we are confident that further progress will follow in 2016."
The TargetAD database is a customised system providing unique information on the link between molecular and cellular changes in brain tissue with AD progression. This database was set up in a multi-year research programme, applying histological, cellular and in vivo target validation procedures.
The database provides a strong platform for systematic and comprehensive target identification and validation as well as compound discovery programmes.